TLC Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq
21 nov. 2018 04h39 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the...
Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain
20 août 2018 08h19 HE
|
Taiwan Liposome Company, Ltd.
Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through Weeks 12, 16, 20, and 24 TLC599 was well-tolerated with no...
TLC Doses First Patients in Phase I/II Trial of TLC590 for Postsurgical Pain Management
14 août 2018 04h55 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the...
TLC Reports Last Patient Last Visit (LPLV) in TLC599 Phase II Trial and FDA Clearance to Commence New Clinical Trials
09 juil. 2018 15h01 HE
|
Taiwan Liposome Company, Ltd.
LPLV marks the final steps toward completion of TLC599 trial for osteoarthritis (OA) painPhase II topline results on-track for 2018 releaseSet to initiate enrollment of US Phase II pharmacokinetic...
TLC Submits IND to US FDA Application for TLC178, Liposomal Vinorelbine Candidate for Pediatric Rhabdomyosarcoma
03 juin 2018 01h00 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan, June 03, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization...
TLC Ranks Top 5% Again in Corporate Governance Evaluations
08 mai 2018 07h45 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan, May 08, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization...
TLC Announces Application with U.S. FDA for Proceeding of TLC590 as Investigational New Drug (IND)
02 avr. 2018 18h59 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan, April 03, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (“TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Files Registration Statement for Proposed Initial Public Offering
17 févr. 2018 04h06 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization...
TLC and Jixi Biotechnology Partners Announce Joint Venture
23 janv. 2018 01h13 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan, Jan. 23, 2018 (GLOBE NEWSWIRE) -- TLC (4152.TT) today announced that it has signed an agreement with Jixi Biotechnology Partners to form a joint venture in TLC Biopharmaceuticals...
TLC to Attend and Present at the 36th Annual JP Morgan Healthcare Forum
05 janv. 2018 05h00 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan, Jan. 05, 2018 (GLOBE NEWSWIRE) -- TLC (4152.TWO) today announced that it will be attending the 36th annual JP Morgan Healthcare Conference in San Francisco on January 7-11, 2018. TLC...